author-photo

Christine Barker

Children's Hospital of Philadelphia

5

Papers

167

Citations

Citation Trend

Filter By

Papers (4) Sort By

Journal Conference Others

Durable Remissions with Humanized CD19-Targeted Chimeric Antigen Receptor (CAR)-Modified T Cells in CAR-Naive and CAR-Exposed Children and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia

2017 Blood
Show All
- Source
- Cite
- Save
Citations (19)
Sustained remissions with CD19-specific chimeric antigen receptor (CAR)-modified T cells in children with relapsed/refractory ALL.

2016 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (84)
Efficacy and Safety of Humanized Chimeric Antigen Receptor (CAR)-Modified T Cells Targeting CD19 in Children with Relapsed/Refractory ALL

2015 Blood
Show All
- Source
- Cite
- Save
Citations (21)
A randomized, multicenter, open-label, phase III study of the Bruton tyrosine kinase (BTK) inhibitor ibrutinib (PCI-32765) versus ofatumumab in patients (pts) with relapsed or refractory (RR) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): RESONATE.

2013 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (14)